U.S. Women’s Health Market Size, Share & Trends Analysis Report By Application (Contraceptives, Endometriosis & Uterine Fibroids), By Age (50 Years & Above, Others), By Drug (Prolia, XGEVA), And Segment Forecasts, 2024 - 2030

Table of Contents

Chapter 1. Methodology and Scope
                   1.1. Market Segmentation & Scope
                   1.2. Segment Definitions
                       1.2.1. Application
                       1.2.2. Age
                       1.2.3. Drug
                       1.2.4. Estimates and forecasts timeline.
                   1.3. Research Methodology
                   1.4. Information Procurement
                       1.4.1. Purchased database.
                       1.4.2. GVR’s internal database
                       1.4.3. Secondary sources
                       1.4.4. Primary research
                       1.4.5. Details of primary research
                       1.4.5.1. Data for primary interviews in U.S.
                   1.5. Information or Data Analysis
                       1.5.1. Data analysis models
                   1.6. Market Formulation & Validation
                   1.7. Model Details
                       1.7.1. Commodity flow analysis (Model 1)
                       1.7.2. Approach 1: Commodity flow approach
                       1.7.3. Volume price analysis (Model 2)
                       1.7.4. Approach 2: Volume price analysis
                   1.8. List of Secondary Sources
                   1.9. List of Primary Sources
                   1.10. Objectives
Chapter 2. Executive Summary
                   2.1. Market Outlook
                   2.2. Segment Outlook
                       2.2.1. Application outlook
                       2.2.2. Age outlook
                       2.2.3. Drug outlook.
                   2.3. Competitive Insights
Chapter 3. U.S. Women’s Health Market Variables, Trends & Scope
                   3.1. Market Lineage Outlook
                       3.1.1. Parent market outlook
                       3.1.2. Related/ancillary market outlook
                   3.2. Market Dynamics
                       3.2.1. Market driver analysis
                           3.2.1.1. Rising incidence of target diseases
                           3.2.1.2. Increasing initiatives by government and various organizations
                           3.2.1.3. Rising publicly funded family planning services
                       3.2.2. Market restraint analysis
                           3.2.2.1. Patent expiry of major drugs
                           3.2.2.2. Lawsuits related to products.
                           3.2.2.3. Adverse effects associated with use of contraceptive drugs and devices.
                   3.3. U.S. Women’s Health Market Analysis Tools
                       3.3.1. Industry Analysis - Porter’s
                           3.3.1.1. Supplier power
                           3.3.1.2. Buyer power
                           3.3.1.3. Substitution threat
                           3.3.1.4. Threat of new entrant
                           3.3.1.5. Competitive rivalry
                       3.3.2. PESTEL Analysis
                           3.3.2.1. Political landscape
                           3.3.2.2. Technological landscape
                           3.3.2.3. Economic landscape
                       3.3.3. Pricing Analysis
Chapter 4. U.S. Women’s Health Market: Application Estimates & Trend Analysis
                   4.1. Application Market Share, 2023 & 2030
                   4.2. Segment Dashboard
                   4.3. U.S. Women’s Health Market by Application Outlook
                   4.4. Market Size & Forecasts and Trend Analyses, 2018 to 2030 for the following
                       4.4.1. Hormonal infertility
                           4.4.1.1. Market estimates and forecasts 2018 to 2030 (USD Million)
                       4.4.2. Contraceptives
                           4.4.2.1. Market estimates and forecasts 2018 to 2030 (USD Million)
                       4.4.3. Postmenopausal osteoporosis
                           4.4.3.1. Market estimates and forecasts 2018 to 2030 (USD Million)
                       4.4.4. Endometriosis & uterine fibroids
                           4.4.4.1. Market estimates and forecasts 2018 to 2030 (USD Million)
                       4.4.5. Menopause
                           4.4.5.1. Market estimates and forecasts 2018 to 2030 (USD Million)
                       4.4.6. Polycystic ovary syndrome (PCOS)
                           4.4.6.1. Market estimates and forecasts 2018 to 2030 (USD Million)
Chapter 5. U.S. Women’s Health Market: Drug Estimates & Trend Analysis
                   5.1. Drug Market Share, 2023 & 2030
                   5.2. Segment Dashboard
                   5.3. U.S. Women’s Health Market by Drug Outlook
                   5.4. Market Size & Forecasts and Trend Analyses, 2018 to 2030 for the following
                       5.4.1. ACTONEL
                           5.4.1.1. Market estimates and forecasts 2018 to 2030 (USD Million)
                       5.4.2. YAZ, Yasmin, Yasminelle
                           5.4.2.1. Market estimates and forecasts 2018 to 2030 (USD Million)
                       5.4.3. FORTEO
                           5.4.3.1. Market estimates and forecasts 2018 to 2030 (USD Million)
                       5.4.4. Minastrin 24 Fe
                           5.4.4.1. Market estimates and forecasts 2018 to 2030 (USD Million)
                       5.4.5. Mirena
                           5.4.5.1. Market estimates and forecasts 2018 to 2030 (USD Million)
                       5.4.6. NuvaRing
                           5.4.6.1. Market estimates and forecasts 2018 to 2030 (USD Million)
                       5.4.7. ORTHO TRI-CY LO
                           5.4.7.1. Market estimates and forecasts 2018 to 2030 (USD Million)
                       5.4.8. Premarin
                           5.4.8.1. Market estimates and forecasts 2018 to 2030 (USD Million)
                       5.4.9. Prolia
                           5.4.9.1. Market estimates and forecasts 2018 to 2030 (USD Million)
                       5.4.10. Reclast/Aclasta
                           5.4.10.1. Market estimates and forecasts 2018 to 2030 (USD Million)
                       5.4.11. XGEVA
                           5.4.11.1. Market estimates and forecasts 2018 to 2030 (USD Million)
                       5.4.12. Zometa
                           5.4.12.1. Market estimates and forecasts 2018 to 2030 (USD Million)
                       5.4.13. Others
                           5.4.13.1. Market estimates and forecasts 2018 to 2030 (USD Million)
Chapter 6. U.S. Women’s Health Market: Age Estimates & Trend Analysis
                   6.1. Age Market Share, 2023 & 2030
                   6.2. Segment Dashboard
                   6.3. U.S. Women’s Health Market by Age Outlook
                   6.4. Market Size & Forecasts and Trend Analyses, 2018 to 2030 for the following
                       6.4.1. 50 years and above
                           6.4.1.1. Market estimates and forecasts 2018 to 2030 (USD Million)
                           6.4.1.2. Postmenopausal osteoporosis
                               6.4.1.2.1. Market estimates and forecasts 2018 to 2030 (USD Million)
                           6.4.1.3. Endometriosis & uterine fibroids
                               6.4.1.3.1. Market estimates and forecasts 2018 to 2030 (USD Million)
                           6.4.1.4. Menopause
                               6.4.1.4.1. Market estimates and forecasts 2018 to 2030 (USD Million)
                           6.4.1.5. Others
                               6.4.1.5.1. Market estimates and forecasts 2018 to 2030 (USD Million)
                       6.4.2. Others
                           6.4.2.1. Market estimates and forecasts 2018 to 2030 (USD Million)
Chapter 7. Competitive Landscape
                   7.1. Recent Developments & Impact Analysis, By Key Market Participants
                   7.2. Company/Competition Categorization
                   7.3. Vendor Landscape
                       7.3.1. List of key distributors and channel partners
                       7.3.2. Key customers
                       7.3.3. Key company market share analysis, 2023
                       7.3.4. AbbVie, Inc.
                           7.3.4.1. Company overview
                           7.3.4.2. Financial performance
                           7.3.4.3. Product benchmarking
                           7.3.4.4. Strategic initiatives
                       7.3.5. Bayer AG
                           7.3.5.1. Company overview
                           7.3.5.2. Financial performance
                           7.3.5.3. Product benchmarking
                           7.3.5.4. Strategic initiatives
                       7.3.6. Merck & Co., Inc.
                           7.3.6.1. Company overview
                           7.3.6.2. Financial performance
                           7.3.6.3. Product benchmarking
                           7.3.6.4. Strategic initiatives
                       7.3.7. Pfizer, Inc.
                           7.3.7.1. Company overview
                           7.3.7.2. Financial performance
                           7.3.7.3. Product benchmarking
                           7.3.7.4. Strategic initiatives
                       7.3.8. Teva Pharmaceutical Industries Ltd.
                           7.3.8.1. Company overview
                           7.3.8.2. Financial performance
                           7.3.8.3. Product benchmarking
                           7.3.8.4. Strategic initiatives
                       7.3.9. Agile Therapeutics
                           7.3.9.1. Company overview
                           7.3.9.2. Financial performance
                           7.3.9.3. Product benchmarking
                           7.3.9.4. Strategic initiatives
                       7.3.10. Amgen, Inc.
                           7.3.10.1. Company overview
                           7.3.10.2. Financial performance
                           7.3.10.3. Product benchmarking
                           7.3.10.4. Strategic initiatives
                       7.3.11. Apothecus Pharmaceutical Corp.
                           7.3.11.1. Company overview
                           7.3.11.2. Financial performance
                           7.3.11.3. Product benchmarking
                           7.3.11.4. Strategic initiatives
                       7.3.12. Eli Lilly and Company
                           7.3.12.1. Company overview
                           7.3.12.2. Financial performance
                           7.3.12.3. Product benchmarking
                           7.3.12.4. Strategic initiatives
                       7.3.13. Ferring B.V.
                           7.3.13.1. Company overview
                           7.3.13.2. Financial performance
                           7.3.13.3. Product benchmarking
                           7.3.13.4. Strategic initiatives

List of Tables

Table 1 List of abbreviation
Table 2 U.S. Women’s Health Market, by application, 2018 - 2030 (USD Million)
Table 3 U.S. Women’s Health Market, by drug, 2018 - 2030 (USD Million)
Table 4 U.S. Women’s Health Market, by age, 2018 - 2030 (USD Million)

List of Figures

Fig. 1 Market research process
Fig. 2 Data triangulation techniques
Fig. 3 Primary research pattern
Fig. 4 Primary interviews in U.S.
Fig. 5 Market research approaches
Fig. 6 Value-chain-based sizing & forecasting
Fig. 7 QFD modeling for market share assessment
Fig. 8 Market formulation & validation
Fig. 9 U.S. Women’s Health Market: market outlook
Fig. 10 Women’s health competitive insights
Fig. 11 Parent market outlook
Fig. 12 Related/ancillary market outlook
Fig. 13 Penetration and growth prospect mapping
Fig. 14 Industry value chain analysis
Fig. 15 U.S. Women’s Health Market driver impact
Fig. 16 U.S. Women’s Health Market restraint impact
Fig. 17 U.S. Women’s Health Market strategic initiatives analysis
Fig. 18 U.S. Women’s Health Market: Application movement analysis
Fig. 19 U.S. Women’s Health Market: Application outlook and key takeaways
Fig. 20 Hormonal infertility market estimates and forecast, 2018 - 2030
Fig. 21 Contraceptives estimates and forecast, 2018 - 2030
Fig. 22 Postmenopausal osteoporosis market estimates and forecast, 2018 - 2030
Fig. 23 Endometriosis & uterine fibroids estimates and forecast, 2018 - 2030
Fig. 24 Menopause market estimates and forecast, 2018 - 2030
Fig. 25 Polycystic ovary syndrome (PCOS) estimates and forecast, 2018 - 2030
Fig. 26 U.S. Women’s Health Market: Drug movement analysis
Fig. 27 U.S. Women’s Health Market: Drug outlook and key takeaways
Fig. 28 ACTONEL market estimates and forecast, 2018 - 2030
Fig. 29 YAZ, Yasmin, Yasminelle estimates and forecast, 2018 - 2030
Fig. 30 FORTEO market estimates and forecast, 2018 - 2030
Fig. 31 Minastrin 24 Fe estimates and forecast, 2018 - 2030
Fig. 32 Mirena market estimates and forecast, 2018 - 2030
Fig. 33 NuvaRing estimates and forecast, 2018 - 2030
Fig. 34 ORTHO TRI-CY LO market estimates and forecast, 2018 - 2030
Fig. 35 Premarin estimates and forecast, 2018 - 2030
Fig. 36 Prolia market estimates and forecast, 2018 - 2030
Fig. 37 Reclast/Aclasta estimates and forecast, 2018 - 2030
Fig. 38 XGEVA market estimates and forecast, 2018 - 2030
Fig. 39 Zometa estimates and forecast, 2018 - 2030
Fig. 40 Others estimates and forecast, 2018 - 2030
Fig. 41 U.S. Women’s Health Market: Age movement Analysis
Fig. 42 U.S. Women’s Health Market: Age outlook and key takeaways
Fig. 43 50 years and above market estimates and forecasts, 2018 - 2030
Fig. 44 Postmenopausal osteoporosis market estimates and forecasts,2018 - 2030
Fig. 45 Endometriosis & uterine fibroids market estimates and forecasts,2018 - 2030
Fig. 46 Menopause market estimates and forecasts,2018 - 2030
Fig. 47 Others market estimates and forecasts, 2018 - 2030
Fig. 48 Others market estimates and forecasts, 2018 - 2030
Fig. 49 Market share of key market players - U.S. Women’s Health Market